Maraviroc + Verapamil = Precautionary

Effect on Concentration

Maraviroc
Increase
Applies within class?
No
Verapamil
No change
Applies within class?
No

Pharmacologic Effects

Maraviroc
Effect
N/A
Applies within class?
No
Verapamil
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 01-Aug-2018

Summary

Sources

Maraviroc versus CYP 3A4 inducers or inhibitors or substrates ^

Study Design

There are no formal interaction studies between these two agents.

Study Results

Limited interaction is expected given the differences in metabolic pathway seen with these two agents.

Study Conclusions

Possible interactions are theoretical and based upon knowledge of metabolic pathways and effects on drug transport proteins. Maraviroc is a substrate of CYP3A4, and verapamil is a moderate inhibitor of this enzyme. No dose adjustments are currently recommended but may be warranted based on clinical monitoring of both safety and efficacy of the combined effect of these agents.

References

Abel S, et al. Effects of cyp3a4 inducers with and without cyp3a4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. British Journal Of Clinical Pharmacology. 2008; : 38-46.